Drugs / Dehydroepiandrosterone (DHEA)
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00900900 | Jul 2009 → Mar 2011 | substance withdrawal syndrome | Jed E. Rose | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00310791 | Apr 2004 → Oct 2009 | anorexia nervosa | Boston Children's Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | dehydroepiandrosterone (DHEA) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00900900 ↗ |
| Action | Restore | “The proposed study will examine whether restoring normal levels of DHEA and estrogen in these young women will increase bone mass during a critical period for bone accretion.” NCT00310791 ↗ |
| Route | Oral | “Patients randomized to the DHEA + HRT arm will receive micronized oral DHEA in a dose of 50 mg daily + HRT” NCT00310791 ↗ |